Vor Biopharma (VOR) Stock Forecast, Price Target & Predictions
VOR Stock Forecast
Vor Biopharma stock forecast is as follows: an average price target of $6.00 (represents a 654.91% upside from VOR’s last price of $0.79) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
VOR Price Target
The average price target for Vor Biopharma (VOR) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 654.91% upside from VOR's last price of $0.79.
VOR Analyst Ratings
According to 4 Wall Street analysts, Vor Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for VOR stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vor Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | - | Goldman Sachs | $6.00 | $5.60 | 7.14% | 654.91% |
The latest Vor Biopharma stock forecast, released on Apr 27, 2022 by Goldman Sachs company, set a price target of $6.00, which represents a 7.14% increase from the stock price at the time of the forecast ($5.60), and a 654.91% increase from VOR last price ($0.79).
Vor Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.79 | $0.79 | $0.79 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Vor Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vor Biopharma's last price of $0.79. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | Barclays | Overweight | Overweight | Hold |
| Nov 14, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 27, 2022 | Wedbush | - | Outperform | Initialise |
Vor Biopharma's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave VOR a "Buy" rating, the same as its previous rate.
Vor Biopharma Financial Forecast
Vor Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VOR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vor Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VOR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vor Biopharma's previous annual EBITDA (undefined) of $NaN.
Vor Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-23.61M | $-20.23M | $-19.87M | $-21.18M | $-23.10M | $-27.54M | $-28.53M |
| High Forecast | $-23.61M | $-20.23M | $-19.87M | $-18.04M | $-14.43M | $-27.54M | $-28.53M |
| Low Forecast | $-23.61M | $-20.23M | $-19.87M | $-23.53M | $-27.43M | $-27.54M | $-28.53M |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VOR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vor Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VOR last annual SG&A of $NaN (undefined).
Vor Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.34 | $-0.30 | $-0.29 | $-0.31 | $-0.34 | $-0.40 | $-0.42 |
| High Forecast | $-0.34 | $-0.30 | $-0.29 | $-0.26 | $-0.21 | $-0.40 | $-0.42 |
| Low Forecast | $-0.34 | $-0.30 | $-0.29 | $-0.34 | $-0.40 | $-0.40 | $-0.42 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vor Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VOR previous annual EPS of $NaN (undefined).
Vor Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $0.97 | $32.50 | 3250.52% | Buy |
| VTYX | Ventyx Biosciences | $1.72 | $33.86 | 1868.60% | Buy |
| STTK | Shattuck Labs | $1.11 | $12.00 | 981.08% | Hold |
| VOR | Vor Biopharma | $0.79 | $6.00 | 659.49% | Buy |
| AUTL | Autolus Therapeutics | $2.80 | $8.87 | 216.79% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
| ERAS | Erasca | $2.64 | $6.50 | 146.21% | Buy |
| FHTX | Foghorn Therapeutics | $7.86 | $16.33 | 107.76% | Buy |
| DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
| BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
| KNSA | Kiniksa Pharmaceuticals | $21.21 | $36.33 | 71.29% | Buy |
| NRIX | Nurix Therapeutics | $22.64 | $32.20 | 42.23% | Buy |
| EWTX | Edgewise Therapeutics | $31.95 | $45.00 | 40.85% | Buy |
| NUVL | Nuvalent | $91.17 | $111.57 | 22.38% | Buy |
| KYMR | Kymera Therapeutics | $44.05 | $51.50 | 16.91% | Buy |
| ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |